Spero Therapeutics Alternatives & Competitors
12 companies similar to Spero Therapeutics — Clinical-stage biotech company focused on rare diseases and diseases with high u...
Companies similar to Spero Therapeutics
Lumos Pharma
Transforming Lives with Rare Focus
Austin, United States
KeifeRx
KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegen...
Mclean, United States
Savara Inc.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases....
United States
Jupiter Neurosciences, Inc.
A clinical-stage drug platform company focused on treating neuroinflammation.
Jupiter, United States
Rival Readout
Competing with Spero Therapeutics? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Sling Therapeutics
Focused on late-stage development of an oral small molecule for the treatment of thyroid e...
Ann Arbor, United States
Allecra Therapeutics
Our Mission: Answering the call to action to fight antibiotic resistance
Pharvaris
Pioneering science for patient choice
Zug, Switzerland
MerLion Pharmaceuticals GmbH
Researches and develops drugs based on natural products
Germany
AnnJi Pharmaceutical Co., Ltd.
Taiwan's Leading New Drug Developer In Dermatology & Neurology
Taiwan
GEn1E Lifesciences Inc.
Clinical-stage, Phase 2 company accelerating novel Precision Therapies for I&I and Rare Di...
Palo Alto, United States
Chance Pharmaceuticals 畅溪制药
A clinical-stage biotech company focusing on discovering, developing and commercializing i...
China
Allena Pharmaceuticals, Inc.
Developing Therapeutics for Patients with Rare and Severe Metabolic and Kidney Disorders
Newton, United States
About Spero Therapeutics
Spero Therapeutics, founded in 2013 and headquartered in the United States, is a multi-asset, clinical-stage biotech company specializing in treatments for multidrug-resistant bacterial infections and rare diseases. With a strong focus on addressing antibiotic resistance, the company is carving out a niche in an increa...
Development of Oral Carbapenem Antibiotics, Drug Pipeline for Rare and MDR Infections, Clinical Trial Execution, Partnership Development
Patients with Complicated Urinary Tract Infections, Patients with Pyelonephritis, Healthcare Providers, Pharmaceutical Collaborators
Biopharmaceutical, Clinical-stage, Biotech Company, Bacterial Infections, Multi-drug Resistant, Rare Diseases, Oral Antimicrobial Agent, IV-administered Agent, Antibiotic, NTM Pulmonary Disease, Complicated Urinary Tract Infections, Business Development, Partnership Directed Programs, Drug Development, Commercialization
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Spero Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Spero Therapeutics on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 14 May 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
